Zobrazeno 1 - 10
of 99
pro vyhledávání: '"Lisa Rydén"'
Autor:
Helena Fohlin, Anna Nordenskjöld, Johan Rosell, Mårten Fernö, Tommy Fornander, Lisa Rydén, Lambert Skoog, Bo Nordenskjöld, Olle Stål
Publikováno v:
Acta Oncologica, Vol 63, Iss 1 (2024)
Background: Hormone receptor positivity predicts benefit from endocrine therapy but the knowledge about the long-term survival of patients with different tumor receptor levels is limited. In this study, we describe the 25 years outcome of tamoxifen (
Externí odkaz:
https://doaj.org/article/70fb0a9414d446158f65dbae4436b48e
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
IntroductionPatients with clinically node-negative breast cancer have a negative sentinel lymph node status (pN0) in approximately 75% of cases and the necessity of routine surgical nodal staging by sentinel lymph node biopsy (SLNB) has been question
Externí odkaz:
https://doaj.org/article/2b42b2bd1a8f4eb9947562a3b55cab65
Autor:
Ida Skarping, Julia Ellbrant, Looket Dihge, Mattias Ohlsson, Linnea Huss, Pär-Ola Bendahl, Lisa Rydén
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-14 (2024)
Abstract Background Surgical sentinel lymph node biopsy (SLNB) is routinely used to reliably stage axillary lymph nodes in early breast cancer (BC). However, SLNB may be associated with postoperative arm morbidities. For most patients with BC undergo
Externí odkaz:
https://doaj.org/article/5b95133ec0ea4882880637b2ce74f48f
Autor:
Helena Jernström, Lisa Rydén
Publikováno v:
The Lancet Regional Health. Europe, Vol 40, Iss , Pp 100896- (2024)
Externí odkaz:
https://doaj.org/article/9db1460f8c6341e3932c15444a00182e
Autor:
Terese Engström, Maria Ekholm, Mårten Fernö, Christine Lundgren, Bo Nordenskjöld, Olle Stål, Pär-Ola Bendahl, Julia Tutzauer, Lisa Rydén
Publikováno v:
Acta Oncologica, Vol 63, Iss 1 (2024)
ABSTRACT Background and purpose: Tamoxifen remains an important adjuvant treatment in premenopausal patients with hormone receptor-positive breast cancer. Thus, determination of hormone receptors is important. Here, we compare cytosol-based methods,
Externí odkaz:
https://doaj.org/article/3af36158a1dc4d0f99ce91c65e6aa575
Autor:
Anna Nordenskjöld, Helena Fohlin, Johan Rosell, Nils-Olof Bengtsson, Tommy Fornander, Thomas Hatschek, Henrik Lindman, Per Malmström, Lisa Rydén, Arne Wallgren, Olle Stål, Bo Nordenskjöld
Publikováno v:
Breast, Vol 71, Iss , Pp 63-68 (2023)
Background: Tamoxifen is an established treatment for breast cancer, but its long-term effects on survival and on secondary cancers are not fully evaluated. Material and methods: We studied 30 years outcome of 4124 postmenopausal patients who were ra
Externí odkaz:
https://doaj.org/article/487528a90ae34cc4bee6e74d37bc5e34
Autor:
Christine Lundgren, Julia Tutzauer, Sarah E. Church, Olle Stål, Maria Ekholm, Carina Forsare, Bo Nordenskjöld, Mårten Fernö, Pär-Ola Bendahl, Lisa Rydén
Publikováno v:
Breast Cancer Research, Vol 25, Iss 1, Pp 1-20 (2023)
Abstract Background Gene expression (GEX) signatures in breast cancer provide prognostic information, but little is known about their predictive value for tamoxifen treatment. We examined the tamoxifen-predictive value and prognostic effects of diffe
Externí odkaz:
https://doaj.org/article/f09fa8d43985469ab9231f4bffcde4a9
Autor:
Kamil Demircan, Ylva Bengtsson, Thilo Samson Chillon, Johan Vallon-Christersson, Qian Sun, Christer Larsson, Martin Malmberg, Lao H. Saal, Lisa Rydén, Åke Borg, Jonas Manjer, Lutz Schomburg
Publikováno v:
Journal of Translational Medicine, Vol 21, Iss 1, Pp 1-12 (2023)
Abstract Introduction Low serum selenium and altered tumour RNA expression of certain selenoproteins are associated with a poor breast cancer prognosis. Selenoprotein expression stringently depends on selenium availability, hence circulating selenium
Externí odkaz:
https://doaj.org/article/cff4db4e410142088f7f14e1fff6b03b
Autor:
Julia Tutzauer, Anna-Maria Larsson, Kristina Aaltonen, Caroline Bergenfelz, Pär-Ola Bendahl, Lisa Rydén
Publikováno v:
Frontiers in Molecular Biosciences, Vol 10 (2024)
Background: Metastatic breast cancer (MBC) is the main cause of breast cancer-related death. The outcome of MBC varies, and there is a lack of biomarkers to aid in prognostication. The primary aim of this study was to evaluate the prognostic value of
Externí odkaz:
https://doaj.org/article/ebdffd1311a14096b6800c44b9cd39c8
Autor:
Frida Björk Gunnarsdottir, Pär-Ola Bendahl, Alexandra Johansson, Rui Benfeitas, Lisa Rydén, Caroline Bergenfelz, Anna-Maria Larsson
Publikováno v:
Breast Cancer Research, Vol 25, Iss 1, Pp 1-15 (2023)
Abstract Background Metastatic breast cancer (MBC) is a challenging disease, and despite new therapies, prognosis is still poor for a majority of patients. There is a clinical need for improved prognostication where immuno-oncology markers can provid
Externí odkaz:
https://doaj.org/article/cef260d99c514fb38e670d1a4eb77c0c